Abstract 14: A switch in metabolic phenotype in vemurafenib-resistant melanoma cells to increased amino acid dependence serves as an alternate mechanism for survival
Authors: Syed Deeba N. , Lall Rahul K. , Soon Yong Wei , Aljohani Ahmed , Guo Changan , Liu Feng , Meyskens Frank L. , Ntambi James M. , Mukhtar Hasan 
Published: July 2016

Despite considerable progress in the understanding of melanoma, and an increase in overall survival, resistance ultimately develops in most patients treated with BRAF inhibitors. To study the molecular mechanism(s) involved in acquired resistance, we generated a Vemurafenib-resistant A2-1b cell line in the BRAFV600E mutated SK-Mel28 melanoma cell background. Viability assays established IC50 of parental SK-Mel28 cells as 0.2 μM, while IC50&gt;12 μM was noted for Vemurafenib-resistant A2-1b cells. Utilizing a quantitative proteomic strategy, profiling of A2-1b versus SK-Mel28 cells resulted in positive identification of 1720 proteins (≤1% FDR). Analysis of this data set identified a subset of 13 proteins, including Enolase 2, Triose-phosphate isomerase and Glyceraldehyde-3-phosphate dehydrogenase with a role in glycolysis, gluconeogenesis and NADH repair, to be differentially regulated in resistant cells. Additional studies validated significantly decreased Enolase 1 and 2 protein expression, suppressed glucose uptake and reduced lactic acid levels in resistant A2-1b cells. The pentose phosphate pathway, in contrast to citric acid cycle intermediates, was unaffected while the latter was significantly suppressed in resistant cells. The energy status of cells was similar as evidenced by equivalent total adenylate, guanylate, NADH, NADP+ and NADPH levels. Flux experiments measuring extracelluar acidification and oxygen consumption rates demonstrated that resistant A2-1b cells are unable to efficiently utilize intrinsic or exogenous fatty acids to meet energy demands. However, A2-1b cells maintained in media deprived of arginine and lysine exhibited increased basal and maximal respiration indicative of an energy reserve that relies on amino acid metabolism. Finally, metabolomics studies showing an overall increase in the absolute concentrations of gluconeogenic and ketogenic amino acids along with significantly elevated S6Kinase expression signify a shift from glucose to amino acids as the major energy source, in resistant A2-1b cells. Our data are consistent with a model of prolonged treatment response in which de-repression of ERK-MAPK pathway activity upon emergence of resistance to Vemurafenib is associated with adaptive changes in cellular metabolism. Sensitivity to BRAF inhibitors in the context of melanoma may not be defined by a reliance on glycolysis for survival, and that switch in metabolic phenotype can serve as an alternate mechanism for cell survival.

Citation Format: Deeba N. Syed, Rahul K. Lall, Yong Wei Soon, Ahmed Aljohani, Changan Guo, Feng Liu, Frank L. Meyskens, James M. Ntambi, Hasan Mukhtar. A switch in metabolic phenotype in vemurafenib-resistant melanoma cells to increased amino acid dependence serves as an alternate mechanism for survival. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 14.